Pacific Biosciences (NASDAQ:PACB) reported quarterly earnings results on February 12, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.12, beating the consensus estimate of $-0.16 by $0.04 per share. Revenue came in at $44.6M, beating the estimate of $41.8M.
Pacific Biosciences's stock moved following the earnings release. The stock currently trades at $1.71 with a market capitalization of $652.1M.